[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$770m800m
Telix's $TLX 2Q25 results are pleasing, with revenue of US$204m. The company is on track to meet its full-year revenue guidance of US$770m800m.
About $770m800m
Summary of social media activity and financial performance related to the topic $770m800m.
Engagements: XX #
Engagements 24-Hour Chart Data
Current Value: XX
Daily Average: XX
1-Year High: XX on 2025-07-24
1-Year Low: X on 2025-07-26
| Social Network | X |
|---|---|
| Engagements | XX |
Mentions: X #
Mentions 24-Hour Chart Data
Current Value: X
Daily Average: X
1-Year High: X on 2025-07-23
1-Year Low: X on 2025-07-23
| Social Network | X |
|---|---|
| Mentions | X |
Creators: X #
Creators 24-Hour Chart Data
X unique social accounts have posts mentioning $770m800m in the last XX hours which is no change from in the previous XX hours
Daily Average: X
1-Year High: X on 2025-07-23
1-Year Low: X on 2025-07-23
Top topics mentioned In the posts about $770m800m in the last XX hours
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Bell Porter: "Telix's $TLX 2Q25 result is pleasing with rev of US$204m comprising Illuccix US$154m andRadioisotope Life Sciences manufacturing of US$46m 1H25 revenue of US$388m slightly beat consensus. The company remains on track to meet unchanged full-year revenue guidance of US$770m800m with Illuccix volume growth suggesting market share gains despite reimbursement headwinds from July. Zircaix remains on track for FDA approval in Aug with other pipeline developments progressing including Gozellix pricing decisions expected by Oct and ethics approval in Australia for TLX101 trials." Buy -"
@ryu_tay on X 2025-07-23 00:48:24 UTC 1125 followers, 1110 engagements